A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (ASSURE-AF).
Phase of Trial: Phase III
Latest Information Update: 07 Sep 2013
At a glance
- Drugs AZD 0837 (Primary) ; Warfarin
- Indications Embolism; Stroke
- Focus Therapeutic Use
- Acronyms ASSURE-AF
- Sponsors AstraZeneca
- 27 Jun 2012 Additional location (Slovakia) added as reported by European Clinical Trials Database.
- 07 Jul 2011 New trial record